Cemdomespib

DB18953InvestigationalSmall molecule

Cemdomespib is under investigation in clinical trial NCT05895552 (A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS)).

Mechanism: Pharmacologically active on Heat shock protein HSP 90-alpha and Heat shock protein HSP 90-beta
Curator reviewed
Formula / weight: C₂₄H₃₀FNO₆ · 447.503 g/mol (avg)
Also known as: Acetamide, n-(2-(5-((6-deoxy-5-c-methyl-4-o-methyl-.alpha.-l-lyxo-hexopyranosyl)oxy)-3'-fluoro(1,1'-biphenyl)-2-yl)ethyl)-
Code names: KU-596 · RTA 901

Resolves to

Compound

UNIIT78QNE8JSICAS1450642-92-8ChEMBLCHEMBL2159227

Structure

InChIKeyPDBWOHBMJQOBHL-WBADGQHESA-NSMILESCO[C@@H]1[C@@H](O)[C@@H](O)[C@H](OC2=CC=C(CCNC(C)=O)C(=C2)C2=CC=CC(F)=C2)OC1(C)C

Targets

P07900HSP90AA1P08238HSP90AB1

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cemdomespib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account